Divi's Laboratories Ltd

IndusInd Bank Ltd, Axis Bank Ltd, Gujarat State Petronet Ltd, Kaynes Technology India Ltd are among the other stocks to see a surge in volumes on BSE today, 12 March 2025.Divis Laboratories Ltd witnessed volume of 24583 shares by 10:47 IST on BSE, a 8.7 times surge over two-week average daily volume of 2824 shares. The stock dropped 0.39% to Rs.5,520.00. Volumes stood at 1781 shares in the last session.IndusInd Bank Ltd clocked volume of 33.57 lakh shares by 10:47 IST on BSE, a 5.52 times surge over two-week average daily volume of 6.08 lakh shares. The stock gained 4.67% to Rs.686.60. Volumes stood at 41.94 lakh shares in the last session.Axis Bank Ltd witnessed volume of 3.43 lakh shares by 10:47 IST on BSE, a 4.56 times surge over two-week average daily volume of 75288 shares. The stock dropped 1.08% to Rs.1,014.50. Volumes stood at 78020 shares in the last session.Gujarat State Petronet Ltd clocked volume of 93113 shares by 10:47 IST on BSE, a 3.86 times surge over two-week average daily volume of 24132 shares. The stock gained 4.85% to Rs.287.65. Volumes stood at 26057 shares in the last session.Kaynes Technology India Ltd saw volume of 1.17 lakh shares by 10:47 IST on BSE, a 3.75 fold spurt over two-week average daily volume of 31128 shares. The stock dropped 3.83% to Rs.4,140.65. Volumes stood at 18528 shares in the last session.Powered by Capital Market - Live

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 6093.9, up 2.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.66% on the day, quoting at 23197.45. The Sensex is at 76616.35, up 0.58%. Divis Laboratories Ltd has gained around 1.73% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 2.9% in last one month and is currently quoting at 21142.05, up 1.98% on the day. The volume in the stock stood at 4.67 lakh shares today, compared to the daily average of 4.35 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6111.6, up 1.98% on the day. Divis Laboratories Ltd is up 63.83% in last one year as compared to a 6.22% spurt in NIFTY and a 16.02% spurt in the Nifty Pharma index.The PE of the stock is 76.41 based on TTM earnings ending December 24.Powered by Capital Market - Live

Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 6146.65, up 0.38% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.38% on the day, quoting at 23607. The Sensex is at 77975.37, down 0.38%. Divis Laboratories Ltd has gained around 4.04% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 5.07% in last one month and is currently quoting at 21868.5, up 0.83% on the day. The volume in the stock stood at 2.2 lakh shares today, compared to the daily average of 4.45 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6170.35, up 0.37% on the day. Divis Laboratories Ltd is up 64.71% in last one year as compared to a 7.64% jump in NIFTY and a 18.78% jump in the Nifty Pharma index.The PE of the stock is 78.43 based on TTM earnings ending December 24.Powered by Capital Market - Live

Divis Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 6074, up 3.23% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.05% on the day, quoting at 23606.2. The Sensex is at 78049.17, up 1.12%. Divis Laboratories Ltd has gained around 3.1% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has gained around 6.05% in last one month and is currently quoting at 21361.6, up 1.48% on the day. The volume in the stock stood at 10.02 lakh shares today, compared to the daily average of 4.03 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 6101.05, up 2.96% on the day. Divis Laboratories Ltd is up 64.18% in last one year as compared to a 8.43% jump in NIFTY and a 18.5% jump in the Nifty Pharma index.The PE of the stock is 85.11 based on TTM earnings ending September 24.Powered by Capital Market - Live

Net profit of Divi's Laboratories rose 64.53% to Rs 589.00 crore in the quarter ended December 2024 as against Rs 358.00 crore during the previous quarter ended December 2023. Sales rose 25.01% to Rs 2319.00 crore in the quarter ended December 2024 as against Rs 1855.00 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales2319.001855.00 25 OPM %32.0426.36 - PBDT825.00584.00 41 PBT726.00489.00 48 NP589.00358.00 65 Powered by Capital Market - Live

Total income grew by 23.13% year on year (YoY) to Rs 2,401 crore in the quarter ended 31 December 2024. Profit before tax for the quarter was at Rs 726 crore, up 48.47% from Rs 489 crore reported in the same period a year ago. Total expenses stood at Rs 1,675 crore in the third quarter of FY25, up 14.65% on YoY basis. Cost of material consumed was at Rs 1,021 crore (up 28.59% YoY) and employee benefit expenses stood at Rs 297 crore (up 10.82% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 10 crore as against a gain of Rs 18 crore posted in Q3 FY24. On nine-month basis, the company's net profit climbed 43.97% to Rs 1,529 crore on 22.25% rise in revenue from operations to Rs 6,775 crore in 9M FY25 over 9M FY24. Forex gain for the nine-month period amounted to Rs 38 crore as against a gain of Rs 32 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Powered by Capital Market - Live

Divis Laboratories will hold a meeting of the Board of Directors of the Company on 3 February 2025.Powered by Capital Market - Live

Divis Laboratories has commenced commercial operations from a part of the Phase I of Unit III greenfield project at Ontimamidi Village (Kona), Thondangi Mandal, Kakinada, Andhra Pradesh from 01 January 2025. The phase I of the Unit III greenfield project of the Company at Kakinada, Andhra Pradesh is being implemented on 200 acres of 500 acres Unit III site, with an estimated investment between Rs 1,200 crore to Rs 1,500 crore. Powered by Capital Market - Live

Divis Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 6075.75, up 1.29% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 1.58% on the day, quoting at 24284.95. The Sensex is at 80244.25, up 1.42%. Divis Laboratories Ltd has added around 4.49% in last one month. Meanwhile, Nifty Pharma index of which Divis Laboratories Ltd is a constituent, has added around 2.89% in last one month and is currently quoting at 21962.05, up 1.07% on the day. The volume in the stock stood at 1.57 lakh shares today, compared to the daily average of 4.48 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 6100.3, up 1.47% on the day. Divis Laboratories Ltd is up 61.58% in last one year as compared to a 22.1% gain in NIFTY and a 39.6% gain in the Nifty Pharma index.The PE of the stock is 86.7 based on TTM earnings ending September 24.Powered by Capital Market - Live

Total income grew by 22.51% year on year (YoY) to Rs 2,444 crore in the quarter ended 30 September 2024. Profit before tax for the quarter was at Rs 722 crore, up 53.94% from Rs 469 crore reported in the same period a year ago. Total expenses stood at Rs 1,722 crore in second quarter of FY25, up 12.84% on YoY basis. Cost of material consumed was at Rs 976 crore (up 37.27% YoY) and employee benefit expenses stood at Rs 304 crore (up 14.29% YoY) during the period under review. Forex gain for the current quarter amounted to Rs 29 crore as against a gain of Rs 11 crore posted in Q2 FY24. On half yearly basis, the company's net profit climbed 33.52% to Rs 940 crore on 20.86% rise in revenue from operations to Rs 4,456 crore in H1 FY25 over H1 FY24. Forex gain for the six month period amounted to Rs 28 crore as against a gain of Rs 14 crore posted in same period a year ago. Divi's Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Shares of Divi's Laboratories declined 0.34% to end at Rs 5,938.15 on Friday, 8 November 2024. Powered by Capital Market - Live